Expanding RINVOQ And SKYRIZI Uses Might Change The Case For Investing In AbbVie (ABBV)
In late June 2026, AbbVie reported multiple product wins, including new pediatric approvals for SKYRIZI, positive CHMP opinions for RINVOQ in alopecia areata and non-segmental vitiligo, and strong Phase 3 lymphoma data for epcoritamab plus lenalidomide versus R-GemOx.
Together, these updates extend AbbVie’s immunology and oncology reach into earlier-stage, high-need patient groups, potentially deepening usage of its existing flagship therapies rather than relying solely on entirely new...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
